Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 4 1Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Carcinoma, Renal Cell 13Sarcoma 10Neoplasms 10Breast Neoplasms 8Neoplasm Metastasis 7Carcinoma, Non-Small-Cell Lung 5Ovarian Neoplasms 3Colorectal Neoplasms 3Advanced Cancers 3Thyroid Neoplasms 2Solid Tumors 2Prostatic Neoplasms 2Pancreatic Neoplasms 2Melanoma 2Lung Neoplasms 2Liver Neoplasms 2Kidney Neoplasms 2Head and Neck Neoplasms 2Wilms Tumor 1Unspecified Adult Solid Tumor, Protocol Specific 1Unspecified Adult Solid Tumor - Protocol Specific 1Thyroid Cancer, Papillary 1Squamous Cell Carcinoma of Head and Neck 1Solid Tumours 1Solid Neoplasm 1Recurrence 1Osteosarcoma 1Optic Nerve Glioma 1Neuroblastoma 1Lymphoma 1

Interventions

Nivolumab 4Ipilimumab 4Specimen Handling 3Magnetic Resonance Spectroscopy 3CTLA-4 Antigen 3Sunitinib 2pembrolizumab 1pazopanib 1fludarabine 1cabozantinib 1belzutifan 1atezolizumab 1aldesleukin 1Immunoglobulin G 1Cyclophosphamide 1Blood Specimen Collection 1Biopsy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Clear-cell metastatic renal cell carcinoma × pazopanib × Clear all
NCT01472081 2021-12-02

Nivolumab (BMS-936558; MDX-1106) in Combination With Sunitinib, Pazopanib, or Ipilimumab in Subjects With Metastatic Renal Cell Carcinoma (RCC) (CheckMate 016)

Bristol-Myers Squibb

Phase 1 Completed
194 enrolled 18 charts
Genitourinary

Clear-cell metastatic renal cell carcinoma, Carcinoma, Renal Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡